Zhejiang Charioteer Pharmaceutical Co. Ltd.

Main study objectives To study the pharmacokinetics of the test acyclovir tablets (specification: 0.4g, produced by Zhejiang Jingxin Pharmaceutical Co., Ltd., licensed by Zhejiang Chetou Pharmaceutical Co., Ltd.) and the reference acyclovir tablets (specification: 400mg, trade name: Zovirax, produced by Glaxo Smithkline Co., Ltd., licensed by Glaxo Smithkline K.K.) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after fasting and fed oral administration. Secondary study objectives To evaluate the safety of the test acyclovir tablets and the reference acyclovir tablets (Zovirax) after a single oral administration in the fasting and fed state in healthy Chinese subjects.

Main study objectives To study the pharmacokinetics of the test formulation (T) famciclovir tablets (specification: 0.25 g, produced by Zhejiang Siwei Pharmaceutical Technology Co., Ltd., provided by Zhejiang Chetou Pharmaceutical Co., Ltd.) and the reference formulation (R) famciclovir tablets (trade name: Famvir, specification: 250 mg, certified by Phoenix Labs, provided by Zhejiang Chetou Pharmaceutical Co., Ltd.) in healthy adult subjects in the fasting and fed state, and to evaluate the bioequivalence of the two formulations. Secondary study objectives To evaluate the safety of the test formulation (T) famciclovir tablets and the reference formulation (R) famciclovir tablets (Famvir) in healthy Chinese subjects in the fasting and fed state.

Main study purpose: According to the relevant provisions of bioequivalence test, valacyclovir hydrochloride tablets (trade name: Veds®, specification: 0.5g (calculated as valacyclovir)) licensed by The Wellcome Foundation Limited were selected as the reference preparation, and the test preparation valacyclovir hydrochloride tablets (specification: 0.5g (calculated as valacyclovir)) licensed by Zhejiang Chetou Pharmaceutical Co., Ltd. were tested for fasting and postprandial human bioequivalence, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation valacyclovir hydrochloride tablets (specification: 0.5g (calculated as valacyclovir)) and the reference preparation valacyclovir hydrochloride tablets (trade name: Veds®, specification: 0.5g (calculated as valacyclovir)) by healthy volunteers.